This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Efstathiou, E. Articles by Logothetis, C. J. Search for Related Content PubMed PubMed Citation Articles by Efstathiou, E. Articles by Logothetis, C. J.

Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer

Authors' Affiliations: Departments of ¹ Genitourinary Medical Oncology, ² Pathology, ³ Biostatistics and Applied Mathematics, ⁴ Urology, and ⁵ Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Christopher J. Logothetis, Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030. Phone: 713-792-2830; Fax: 713-745-1625; E-mail: clogothe{at}mdanderson.org.

Purpose: Disruption of stromal-epithelial interactions favoring prostate cancer progression may affect the phenotype of the disease. We did a preoperative study to test the hypothesis that thalidomide, an active agent in metastatic disease, is a modulator of the tumor microenvironment.

Experimental Design: Eighteen men with high-risk prostate cancer were given thalidomide at doses escalated to 600 mg for 12 weeks, followed by radical prostatectomy. We constructed tissue microarrays from prostatectomy specimens from 15 treated patients and 15 matched untreated control subjects to assess effects of thalidomide on the tumor microenvironment. We compared the immunohistochemical expression of three groups of markers linked to angiogenesis, stromal-epithelial interactions, or the epithelial compartment. Levels of circulating basic fibroblast growth factor, interleukin-6, tumor necrosis factor-, and vascular endothelial growth factor were also assessed.

Results: Thalidomide was well tolerated and induced a median reduction in prostate-specific antigen of 41% without affecting testosterone. Tissue microarray analyses indicated modulation of vascular marker expression accompanied by a reduction in microvessel density in the treated group. Comparison of broader stromal-epithelial interaction markers between treated and control groups suggested a transition to a less aggressive phenotype as a result of thalidomide treatment. Hedgehog signaling was attenuated and the ratio of matrix metalloproteinases to E-cadherin shifted to favor E-cadherin. No differences were noted in proliferation or apoptosis in the epithelial compartment.

Conclusions: These findings are the first clinical evidence to support the hypothesis that the reported thalidomide clinical efficacy is attributable to early modulation of the tumor microenvironment and suggest that stromal-targeting therapies will be effective against prostate cancer.

This article has been cited by other articles:

				J. A. Garcia, E. A. Klein, C. Magi-Galluzzi, P. Elson, P. Triozzi, and R. Dreicer Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3052 - 3059. [Abstract] [Full Text] [PDF]

				C. J. Logothetis, N. M. Navone, and S.-H. Lin Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1599 - 1602. [Abstract] [Full Text] [PDF]

				W. Arap, M. Trepel, B. R. Zetter, and R. Pasqualini Meeting Report: Innovations in Prostate Cancer Research Cancer Res., February 1, 2008; 68(3): 635 - 638. [Full Text] [PDF]